Research Article
Anatomic Subsites and Prognosis of Gastric Signet Ring Cell Carcinoma: A SEER Population-Based 1 : 1 Propensity-Matched Study
Table 4
Patients’ baseline characteristics after PSM.
| | Characteristic | PGC | OGC | value | DGC | OGC | value | | 220 | 220 | 310 | 310 |
| | Age (%) | 18-49 | 40 (18.2) | 48 (21.8) | 0.514 | 72 (23.2) | 68 (21.9) | 0.812 | | 50-59 | 59 (26.8) | 60 (27.3) | | 74 (23.9) | 81 (26.1) | | | 60-69 | 57 (25.9) | 60 (27.3) | | 70 (22.6) | 73 (23.5) | | | 70-79 | 49 (22.3) | 35 (15.9) | | 66 (21.3) | 56 (18.1) | | | ≥80 | 15 (6.8) | 17 (7.7) | | 28 (9.0) | 32 (10.3) | | | Race (%) | White | 167 (75.9) | 164 (74.5) | 0.886 | 223 (71.9) | 222 (71.6) | 0.957 | | Black | 20 (9.1) | 25 (11.4) | | 42 (13.5) | 41 (13.2) | | | API | 32 (14.5) | 30 (13.6) | | 42 (13.5) | 45 (14.5) | | | AI | 1 (0.5) | 1 (0.5) | | 3 (1.0) | 2 (0.6) | | | Gender (%) | Male | 129 (58.6) | 137 (62.3) | 0.495 | 146 (47.1) | 155 (50.0) | 0.52 | | Female | 91 (41.4) | 83 (37.7) | | 164 (52.9) | 155 (50.0) | | | Marital status (%) | Divorced | 32 (14.5) | 28 (12.7) | 0.858 | 33 (10.6) | 31 (10.0) | 0.827 | | Married | 131 (59.5) | 128 (58.2) | | 194 (62.6) | 192 (61.9) | | | Widowed | 19 (8.6) | 20 (9.1) | | 30 (9.7) | 37 (11.9) | | | Single | 38 (17.3) | 44 (20.0) | | 53 (17.1) | 50 (16.1) | | | Grade (%) | I | 0 | 0 | 0.966 | 0 (0.0) | 1 (0.3) | 0.646 | | II | 3 (1.4) | 3 (1.4) | | 5 (1.6) | 7 (2.3) | | | III | 210 (95.5) | 209 (95.0) | | 299 (96.5) | 294 (94.8) | | | IV | 7 (3.2) | 8 (3.6) | | 6 (1.9) | 8 (2.6) | | | TNM stage (%) | I | 29 (13.2) | 34 (15.5) | 0.718 | 47 (15.2) | 44 (14.2) | 0.907 | | II | 35 (15.9) | 29 (13.2) | | 39 (12.6) | 44 (14.2) | | | III | 76 (34.5) | 71 (32.3) | | 115 (37.1) | 110 (35.5) | | | IV | 80 (36.4) | 86 (39.1) | | 109 (35.2) | 112 (36.1) | | | Tumor size (%) | ≤2 cm | 31 (14.1) | 23 (10.5) | 0.439 | 26 (8.4) | 29 (9.4) | 0.937 | | ≤5 cm | 35 (15.9) | 41 (18.6) | | 51 (16.5) | 53 (17.1) | | | >5 cm | 70 (31.8) | 62 (28.2) | | 103 (33.2) | 105 (33.9) | | | Unknown | 84 (38.2) | 94 (42.7) | | 130 (41.9) | 123 (39.7) | | | Regional nodes examined (%) | ≤16 | 160 (72.7) | 162 (73.6) | 0.914 | 196 (63.2) | 206 (66.5) | 0.449 | | >16 | 60 (27.3) | 58 (26.4) | | 114 (36.8) | 104 (33.5) | | | Bone metastasis (%) | Yes | 13 (5.9) | 16 (7.3) | 0.701 | 7 (2.3) | 7 (2.3) | 1 | | No | 207 (94.1) | 204 (92.7) | | 303 (97.7) | 303 (97.7) | | | Liver metastasis (%) | Yes | 8 (3.6) | 13 (5.9) | 0.371 | 17 (5.5) | 9 (2.9) | 0.161 | | No | 212 (96.4) | 207 (94.1) | | 293 (94.5) | 301 (97.1) | | | Lung metastasis (%) | Yes | 8 (3.6) | 9 (4.1) | 1 | 10 (3.2) | 9 (2.9) | 1 | | No | 212 (96.4) | 211 (95.9) | | 300 (96.8) | 301 (97.1) | | | Surgery (%) | No | 101 (45.9) | 105 (47.7) | 0.774 | 123 (39.7) | 129 (41.6) | 0.683 | | Yes | 119 (54.1) | 115 (52.3) | | 187 (60.3) | 181 (58.4) | | | Radiation (%) | No/unknown | 160 (72.7) | 165 (75.0) | 0.664 | 245 (79.0) | 251 (81.0) | 0.616 | | Yes | 60 (27.3) | 55 (25.0) | | 65 (21.0) | 59 (19.0) | | | Chemotherapy (%) | No/unknown | 61 (27.7) | 63 (28.6) | 0.916 | 108 (34.8) | 102 (32.9) | 0.671 | | Yes | 159 (72.3) | 157 (71.4) | | 202 (65.2) | 208 (67.1) | |
|
|
